Ampullary Cancer Ampullary Cancer [Member] Ampullary Cancer Business Combinations Policy Business Combinations Policy [Policy Text Block] Olumiant® Olumiant [Member] Olumiant [Member] Document Type Document Type Other–net, (income) expense Other (income) expense Other Nonoperating Income (Expense) Contingencies Commitments and Contingencies Disclosure [Text Block] Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Common Stock in Treasury Treasury Stock [Member] 1.000% Notes due 2022 1.000% Notes Due June 2, 2022 [Member] 1.000% Notes Due June 2, 2022 [Member] Deferred income taxes assumed Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Lebrikizumab Lebrikizumab [Member] Lebrikizumab [Member] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Retirement Benefits Retirement Benefits [Text Block] Milestone Payments, Success-based Regulatory Milestone Payments, Success-based Regulatory [Member] Milestone Payments, Success-based Regulatory Cash and cash equivalents at January 1 Cash and Cash Equivalents at March 31 Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Schedule of components of other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] China CHINA Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Other Diabetes Other Diabetes [Member] Other Diabetes [Member] Dermira Dermira, Inc. [Member] Dermira, Inc. [Member] 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Liabilities and Equity Liabilities and Equity [Abstract] Deferred tax liabilities Deferred Income Tax Liabilities, Net Receivables, Net, Current [Abstract] Receivables, Net, Current [Abstract] Security Exchange Name Security Exchange Name Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. [Member] Rigel Pharmaceuticals, Inc. Total current liabilities Liabilities, Current Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Severance Severance Costs Schedule of amounts recorded for contract liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Limited initial market entry, supply term Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and Contingencies (Note 9) Commitments and Contingencies Noncurrent investments, debt securities Debt Securities, Available-for-sale, Noncurrent Purchases of common stock Payments for Repurchase of Common Stock Assets Assets [Abstract] Cash acquired Cash Acquired from Acquisition Stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Income taxes payable Taxes Payable, Current Entity Address, State or Province Entity Address, State or Province Accounts payable Accounts Payable, Current Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Other receivables Derivative Asset, Current Retained earnings Retained Earnings (Accumulated Deficit) Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Eli Lilly and Company Shareholders’ Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Derivative liability, notional amount Derivative Liability, Notional Amount Merus N.V. Merus N.V. [Member] Merus N.V. Asset impairment and other special charges Asset Impairment Charges (Recoveries) And Other Special Charges Asset Impairment Charges (Recoveries) And Other Special Charges Southern District of California Southern District Of California [Member] Southern District Of California Hedging Designation [Domain] Hedging Designation [Domain] Shanghai Junshi Biosciences Co., Ltd. Junshi Biosciences [Member] Junshi Biosciences Other noncurrent liabilities Other Liabilities, Noncurrent Deferred tax assets Deferred Income Tax Assets, Net Employee Litigation Employee Litigation [Member] Employee Litigation [Member] Available-for-sale, percentage of nonperforming assets Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Other investing activities, net Payments for (Proceeds from) Other Investing Activities Brazil BRAZIL AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Document Information [Table] Document Information [Table] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Alternative investments, unfunded commitments, payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Inventories Inventory, Net Business Acquisition [Axis] Business Acquisition [Axis] Plaintiff Allegations [Axis] Plaintiff Allegations [Axis] Plaintiff Allegations Schedule of asset acquisitions Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Geographical [Domain] Geographical [Domain] 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Estimated future employer contributions in current fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Statement [Line Items] Statement [Line Items] Innovent Biologics, Inc. Innovent Biologics, Inc. [Member] Innovent Biologics, Inc. Other Neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Class of Stock [Domain] Class of Stock [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Statement [Table] Statement [Table] Number of claimants Loss Contingency, Number Of Claimants Loss Contingency, Number Of Claimants Interest cost Defined Benefit Plan, Interest Cost Byetta Byetta [Member] Byetta More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] U.S. government and agency securities US Government Agencies Debt Securities [Member] Other noncurrent liabilities Derivative Liability, Noncurrent Schedule of effects of risk-management instruments were recognized in other–net, (income) expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Milestones capitalized Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Terms or rights and obligations under collaborative arrangements. Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Business Combinations [Abstract] Business Combinations [Abstract] Basaglar® Basaglar Basaglar [Member] Basaglar [Member] Entity Small Business Entity Small Business Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Royalty Agreement Terms Royalty Agreement Terms [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Contingent value right, monthly reduction (in cents per share) Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs Prepaid expenses and other Prepaid Expense, Current Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Amendment Flag Amendment Flag Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Schedule of the amounts recognized for assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Summary certain fair value information Fair Value, Assets Measured on Recurring Basis [Table Text Block] Other, net of tax Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Entity Central Index Key Entity Central Index Key Fair value of CVR liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Short-term investments, debt securities Debt Securities, Available-for-sale, Current Precision Biosciences, Inc. Precision Biosciences, Inc. [Member] Precision Biosciences, Inc. Derivative Instrument [Axis] Derivative Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Fair value, by balance sheet grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Net change in short-term borrowings Proceeds from Short-term Debt Description of Derivative Risk Management Policy Derivatives, Policy [Policy Text Block] Geographical [Axis] Geographical [Axis] Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Taltz® Taltz [Member] Taltz [Member] Unrealized gross gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Long-term income taxes payable Accrued Income Taxes, Noncurrent Allowances for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Verzenio® Verzenio [Member] Verzenio [Member] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Effective portion of cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Outside US And Japan Outside US And Japan [Member] Outside US And Japan Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Marketing, selling, and administrative Selling, General and Administrative Expense Other securities, current investments Other Debt Obligations [Member] Derivative, notional amount Derivative, Notional Amount Foreign currency exchange contracts Foreign Exchange Contract [Member] Other noncurrent assets Other Assets, Noncurrent Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Intangible asset impairment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Pancreatitis Pancreatitis [Member] Pancreatitis Other current liabilities Derivative Liability, Current Equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Title of 12(b) Security Title of 12(b) Security Equity securities, net unrealized gains Net investment gains Equity Securities, FV-NI, Gain (Loss) Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Weiler v. Takeda Canada Inc. et al. Whyte Et Al. V. Eli Lilly Et Al. [Member] Whyte Et Al. V. Eli Lilly Et Al. Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Interest expense Interest Expense Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Other Oncology Other Oncology [Member] Other Oncology [Member] Other Stockholders' Equity, Other Depreciation and amortization Depreciation, Depletion and Amortization Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Summary of the fair value of available-for-sale securities in an unrealized gain or loss position Unrealized Gain (Loss) on Investments [Table Text Block] Product and Service [Axis] Product and Service [Axis] Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Foreign currency-denominated notes Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Amount of receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Retirement Plan Type [Axis] Retirement Plan Type [Axis] Outside U.S. Non-US [Member] Asahi Kasei Pharma Corporation Asahi Kasei Pharma Corporation [Member] Asahi Kasei Pharma Corporation Fair value of securities in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position Acquired in-process research and development (Note 3) Acquired in-process research and development The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Additional Paid-in Capital Additional Paid-in Capital [Member] Schedule of other–net, (income) expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Fair Value Hedging Fair Value Hedging [Member] Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Japan JAPAN Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Alimta® Alimta [Member] Alimta [Member] Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Litigation Case [Axis] Litigation Case [Axis] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Swap Swiss Francs to U.S. Dollars Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Research and development Research and Development Expense Collaboration and other revenue associated with prior period transfers of intellectual property Royalty [Member] Erbitux® Erbitux [Member] Erbitux [Member] Cash paid for acquisitions, net of cash acquired (Note 3) Cash paid, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Employee Benefit Trust Trust for Benefit of Employees [Member] 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] Derivatives used in net investment hedge, net of tax Derivatives used in Net Investment Hedge, Net of Tax Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Costs, expenses, and other Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Immunology Immunology [Member] Immunology [Member] Current Assets Assets, Current [Abstract] Interest income Investment Income, Interest Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Product Liability Product Liability [Member] Product Liability Domicile of Litigation [Axis] Domicile Of Litigation [Axis] Domicile Of Litigation Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Legal Entity [Axis] Legal Entity [Axis] City Area Code City Area Code Document Period End Date Document Period End Date Contingent consideration liability, other noncurrent liabilities Business Combination, Contingent Consideration, Liability Net investment hedges Net Investment Hedging [Member] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Net income (loss) Net income Total reclassifications, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Hedging Designation [Axis] Hedging Designation [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Net purchases of property and equipment Payments to Acquire Productive Assets Equity securities Equity Securities, FV-NI Other Other Product, Total [Member] Other Product, Total [Member] Entity [Domain] Entity [Domain] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Designated as Hedging Instrument Designated as Hedging Instrument [Member] Cover [Abstract] Cover [Abstract] The components of the charges included in asset impairment, restructuring, and other special charges Restructuring and Related Costs [Table Text Block] Summary the contractual maturities of our investments in debt securities measured at fair value Debt Securities, Available-for-sale [Table Text Block] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member] Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities Long-term debt, including current portion Long-term debt, including current portion Long-term Debt Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Weiler v. Takeda Canada Inc. et al. Weiler V. Takeda Canada Inc. Et Al. [Member] Weiler V. Takeda Canada Inc. Et Al. Pension contributions Payment for Pension Benefits Collaborative arrangement, rights and obligations, percentage (up to) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Service cost Defined Benefit Plan, Service Cost Other–Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Cost of sales Cost of Goods and Services Sold Total Debt Securities, Available-for-sale Trulicity® Trulicity [Member] [Member] Trulicity [Member] [Member] Equity Components [Axis] Equity Components [Axis] Number of pending lawsuits Loss Contingency, Pending Claims, Number Humalog, Humulin and Forteo Humalog, Humulin, And Forteo [Member] Humalog, Humulin, And Forteo Number of requests for information Loss Contingency, Number Of Requests For Information Loss Contingency, Number Of Requests For Information Purchases of in-process research and development Purchased in-process research and development The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS). Cyramza® Cyramza [Member] Cyramza [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Diabetes Diabetes [Member] Diabetes [Member] Long-term debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Europe Europe [Member] Various State Domiciles Various State Domiciles [Member] Various State Domiciles Other Other Product [Member] Other Product [Member] Buy British Pounds and Sell U.S. Dollars Buy British Pound and Sell US Dollars [Member] Buy British Pound and Sell US Dollars [Member] Summary certain fair value information, liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Asset-backed securities Asset-backed Securities [Member] Entity Interactive Data Current Entity Interactive Data Current Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss U.S. UNITED STATES Financial Instruments Fair Value Disclosures [Text Block] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Forward-starting interest rate swaps Interest Rate Swap [Member] Actuarial losses, net Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Business Acquisition [Line Items] Business Acquisition [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Epp v. Takeda Canada Inc. et al. Epp V. Takeda Canada Inc. Et Al. [Member] Epp V. Takeda Canada Inc. Et Al. Retirement Plan Type [Domain] Retirement Plan Type [Domain] Contingent value right, additional price per share (up to) (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Tanezumab Tanezumab [Member] Tanezumab [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable, net of allowances of $23.9 (2021) and $25.9 (2020) Accounts Receivable, after Allowance for Credit Loss, Current Unrealized gross losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cymbalta® Cymbalta [Member] Cymbalta [Member] Effective Portion of Cash Flow Hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Milestone Payments, Capitalized as Intangible Assets Milestone Payments, Capitalized As Intangible Assets [Member] Milestone Payments, Capitalized As Intangible Assets Goodwill Goodwill Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Document Transition Report Document Transition Report Purchases of noncurrent investments Payments to Acquire Long-term Investments 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Equity [Abstract] Equity [Abstract] Derivative asset, notional amount Derivative Asset, Notional Amount Activity related to our available-for-sale securities Gain (Loss) on Securities [Table Text Block] Net change in short-term borrowings Repayments of Short-term Debt Derivative Contract [Domain] Derivative Contract [Domain] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Litigation Case Type [Domain] Litigation Case [Domain] Basic (in usd per share) Earnings Per Share, Basic Entity File Number Entity File Number Sitryx Therapeutics Limited Sitryx Therapeutics Limited [Member] Sitryx Therapeutics Limited [Member] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Accrued retirement benefits (Note 8) Liability, Defined Benefit Plan, Noncurrent Cost Portion at Other than Fair Value Measurement [Member] Net Cash (Used for) Provided by Financing Activities Net Cash Provided by (Used in) Financing Activities Repayments of long-term debt Repayments of long-term debt Repayments of Long-term Debt Non-CHINA Non-CHINA [Member] Non-CHINA Number of plaintiffs Loss Contingency, Number of Plaintiffs Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock Common Stock, Value, Issued Investments (Note 6) Noncurrent investments Long-term Investments Document Fiscal Year Focus Document Fiscal Year Focus Equity method investments Other Long-term Investments Other Immunology Other Immunology [Member] Other Immunology [Member] Entity Current Reporting Status Entity Current Reporting Status Short-term borrowings and current maturities of long-term debt Debt, Current Retirement Benefits [Abstract] Retirement Benefits [Abstract] Number of patents, claims dismissed Loss Contingency, Number Of Patents, Claims Dismissed Loss Contingency, Number Of Patents, Claims Dismissed Other comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Los Angeles Los Angeles [Member] Los Angeles Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and cash equivalents (Note 6) Cash and Cash Equivalents, at Carrying Value COVID-19 Antibodies COVID-19 Antibodies [Member] COVID-19 Antibodies Employee benefit trust Common Stock, Shares Held in Employee Trust Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Mortgage-backed securities Collateralized Mortgage Backed Securities [Member] Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Long-term debt Long-term Debt, Excluding Current Maturities Recognized actuarial loss Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit Total Eli Lilly and Company shareholders’ equity Stockholders' Equity Attributable to Parent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Purchase price Business Combination, Consideration Transferred Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Total liabilities and equity Liabilities and Equity Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accumulated other comprehensive loss (Note 10) Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Total other liabilities Liabilities, Noncurrent Entity Address, City or Town Entity Address, City or Town Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Employee compensation Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Acquired IPR&D Expense Payments to Acquire Intangible Assets Damages awarded, value Loss Contingency, Damages Awarded, Value Acquisition date fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Hedging Relationship [Axis] Hedging Relationship [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Net product revenue Product [Member] Equity Component [Domain] Equity Component [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Other noncurrent assets Derivative Asset, Noncurrent Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Dividends paid Payments of Dividends Property and equipment, net of accumulated depreciation of $9,643.4 (2021) and $9,570.7 (2020) Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Actos Actos [Member] Actos Interest rate contracts Interest Rate Contract [Member] Net income Net Income (Loss) Attributable to Parent Domicile of Litigation [Domain] Domicile Of Litigation [Domain] Domicile Of Litigation Other current liabilities Other Liabilities, Current Other comprehensive income (loss), net of tax (Note 10) Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Earnings per share: Earnings Per Share [Abstract] Tyvyt® TYVYT [Member] TYVYT Pancreatic Cancer or Thyroid Cancer Pancreatic Cancer Or Thyroid Cancer [Member] Pancreatic Cancer Or Thyroid Cancer Acquired IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-term Investments Document Fiscal Period Focus Document Fiscal Period Focus Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Milestone Payments, Success-based Regulatory and Sales-based Milestone Payments, Success-based Regulatory And Sales-based [Member] Milestone Payments, Success-based Regulatory And Sales-based Emgality® Emgality [Member] Emgality [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Other receivables Other Receivables, Net, Current 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] Payment for additional discretionary funding Payment for Pension Benefits, Additional Discretionary Funding Payment for Pension Benefits, Additional Discretionary Funding Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Schedule of significant milestones and revenue recognized Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Dr Reddy's Lab Dr Reddy's Lab [Member] Dr Reddy's Lab [Member] Schedule of reclassifications out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) Recognized Cialis® Cialis [Member] Cialis [Member] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Benefit (provision) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Other securities, noncurrent investments Other Equity Securities [Member] Other Equity Securities [Member] Proceeds from sales of noncurrent investments Proceeds from Sale of Long-term Investments Dividends payable Dividends Payable, Current Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Common Stock (no par value) Common Class A [Member] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other–net, (income) expense (Note 11) Other–net, (income) expense Nonoperating Income (Expense) Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Foreign Currency Translation Gains (Losses) Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Costs, expenses, and other: Costs and Expenses [Abstract] Document Information [Line Items] Document Information [Line Items] Unrealized Net Gains (Losses) on Securities Unrealized net gains/losses on securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Cash Flow Hedging Cash Flow Hedging [Member] Consideration transferred, number of contingent value rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Loss Contingencies [Table] Loss Contingencies [Table] Carrying Amount Reported Value Measurement [Member] Revenue Revenue from Contract with Customer [Text Block] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Prevail Therapeutics Inc. Prevail Therapeutics Inc. [Member] Prevail Therapeutics Inc. Humulin® Humulin [Member] Humulin [Member] Revenue (Note 2) Revenue Revenues Class of Stock [Axis] Class of Stock [Axis] Income taxes (Note 7) Tax benefit Income Tax Expense (Benefit) Jardiance Jardiance [Member] Jardiance [Member] Humalog® Humalog [Member] Humalog [Member] Plaintiff Allegations [Domain] Plaintiff Allegations [Domain] Plaintiff Allegations Number of patents ruled unpatentable Loss Contingency, Number Of Patents Ruled Unpatentable Loss Contingency, Number Of Patents Ruled Unpatentable Diluted (in usd per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Forteo® Forteo [Member] Forteo [Member] Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Entity Address, Address Line One Entity Address, Address Line One Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Contract liabilities Contract with Customer, Liability Entity Emerging Growth Company Entity Emerging Growth Company Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Roche Roche [Member] Roche [Member] Buy U.S. Dollars Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Buy Euros Sell U.S. Dollars Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Buy U.S. Dollars Sell Euros Buy Us Dollar Sell Euro [Member] Foreign Currency Forward commitment to Buy US dollar Sell euro Noncontrolling Interests Noncontrolling Interest [Member] Net investment gains Gain (Loss) on Investments Purchases of short-term investments Payments to Acquire Short-term Investments Alternative investments, unfunded commitments Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Retained Earnings Retained Earnings [Member] Measurement Basis [Axis] Measurement Basis [Axis] Collaborative arrangement, rights and obligations, terms, annual net sales threshold (up to) Collaborative Arrangement, Rights and Obligations, Terms, Annual Net Sales Threshold Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold Schedule of net pension and retiree health benefit (income) cost Schedule of Net Benefit Costs [Table Text Block] Effective income tax rate, percentage Effective Income Tax Rate Reconciliation, Percent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Swap U.S. Dollars to Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro [Member] Other Liabilities Liabilities, Noncurrent [Abstract] Retiree Health Benefit Plans Other Postretirement Benefits Plan [Member] Corporate debt securities Corporate Debt Securities [Member] Trading Symbol Trading Symbol Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Cost of common stock in treasury Treasury Stock, Value Asset impairment, restructuring, and other special charges (Note 5) Total asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Defined Benefit Pension Plans Pension Plan [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current Liabilities Liabilities, Current [Abstract] Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted Description of Derivative Activity Volume Percent Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2 Entity Shell Company Entity Shell Company AbCellera Biologics Inc. AbCellera Biologics Inc. [Member] AbCellera Biologics Inc. [Member] Zyprexa® Zyprexa [Member] Zyprexa [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Short-term investments (Note 6) Short-term Investments